Assessing age and gender in studies of breakthrough pain medications

References

• Deandrea S, Montanari M, Moja L, et al. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008;19:1985-91
   PubMed Web of Science ®Google Scholar
• Mercadante S, Arcuri E. Pharmacological management of cancer pain in the elderly. Drugs Aging 2007;24:761-76
   PubMed Web of Science ®Google Scholar
• Mercadante S, Casuccio A, Pumo S, et al. Factors influencing the opioid response in advanced cancer patients with pain followed at home: the effects of age and gender. Support Care Cancer 2000;8:123-30
   PubMed Web of Science ®Google Scholar
• Green CR, Hart-Johnson T. Cancer pain: an age-based analysis. Pain Med 2010;11:1525-36
   PubMed Web of Science ®Google Scholar
• Viganó A, Bruera E, Suarez-Almazor ME. Age, pain intensity, and opioid dose in patients with advanced cancer. Cancer 1998;83:1244-50
   PubMed Web of Science ®Google Scholar
• Hall S, Gallagher RM, Gracely E, et al. The terminal cancer patient: effects of age, gender, and primary tumor site on opioid dose. Pain Med 2003;4:125-34
   PubMed Web of Science ®Google Scholar
• Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs 2012;72:181-90
   PubMed Web of Science ®Google Scholar
• Zeppetella G, Davies A, Eijgelshoven I, Jansen JP. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manag 2013, epub ahead of print. doi:10.1016/j.jpainsymman.2013.05.020
   Google Scholar
• Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Ntl Cancer Inst 1998;90:611-16
   PubMed Web of Science ®Google Scholar
• Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release (MSIR). Pain 2001;91:123-30
   PubMed Web of Science ®Google Scholar
• Mercadante S, Villari P, Ferrera P, et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer 2007;96:1828-33
   PubMed Web of Science ®Google Scholar
• Mercadante S, Radbruck L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomized, crossover trial. Curr Med Res Opin 2009;25:2805-15
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805-11
   PubMed Web of Science ®Google Scholar
• Slatkin N, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Supp Oncol 2007;5:327-34
   PubMedGoogle Scholar
• Ashburn MA, Slevin KA, Messina J, et al. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anesth Analg 2011;112:693-702
   PubMed Web of Science ®Google Scholar
• Webster LR, Slevin KA, Narayana A, et al. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes. Pain Med 2013;14:1332-45
   PubMed Web of Science ®Google Scholar
• Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009;25:2877-85
   PubMed Web of Science ®Google Scholar
• Lennernäs B, Frank-Lissbrant I, Lennernäs H, et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Palliat Med 2010;24:286-93
   PubMed Web of Science ®Google Scholar
• Kress HG, Ororiska A, Kaczmarek Z, et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 100 µg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther 2009;31:1177-91
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Burton AW, Gabrail N, et al. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010;151:617-24
   PubMed Web of Science ®Google Scholar
• Fallon M, Reale C, Davies A, et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Supp Oncol 2011;9:224-31
   PubMedGoogle Scholar
• Davies A, Sitte T, Elsner F, et al. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manag 2011;41:358-66
   PubMed Web of Science ®Google Scholar
• Rauck R, North J, Gever LN, et al. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol 2010;21:1308-14
   PubMed Web of Science ®Google Scholar
• Rauck R, Reynolds L, Geach J, et al. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2012;28:859-70
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81
   PubMed Web of Science ®Google Scholar
• Davies A, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Association of Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009;13:331-8
   PubMed Web of Science ®Google Scholar
• Bijur PE, Esses D, Birnbaum A, et al. Response to morphine in male and female patients: analgesia and adverse effects. Clin J Pain 2008;24:192-8
   PubMed Web of Science ®Google Scholar
• Mercadante S, Ferrera P, Villari P, et al. Opioid escalation in patients with cancer pain: the effect of age. J Pain Symptom Manag 2006;32:413-19
   PubMed Web of Science ®Google Scholar
• Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol 2011;80:460-5
   PubMed Web of Science ®Google Scholar
• Gagliese L. Aging and the management of cancer pain. Ann Oncol 2009;20:1752
   PubMed Web of Science ®Google Scholar